Is Verteporfin Used as a Topical Treatment, Injection, or Oral Medication for Hair Loss?

Understanding What Verteporfin Actually Is

Verteporfin is a medication approved by the United States Food and Drug Administration (FDA) for the treatment of age-related macular degeneration, a serious eye condition involving abnormal blood vessel growth beneath the retina. According to the FDA label for Visudyne (verteporfin for injection), the drug is given as an intravenous infusion and then activated by a specific wavelength of light, in a process known as photodynamic therapy. It is not approved as an oral medication, and it is not formulated as a topical cream or solution for skin or scalp application (FDA, 2000).

In ophthalmology, verteporfin accumulates in abnormal blood vessels and, when exposed to laser light, generates reactive oxygen species — chemically reactive oxygen-containing molecules that damage the targeted cells. This controlled damage helps close off unwanted blood vessels in the eye. The mechanism is documented in clinical studies of verteporfin photodynamic therapy for macular degeneration and for central serous chorioretinopathy (Chan et al., 2008).

Verteporfin is not approved by the FDA or the European Medicines Agency for the treatment of hair loss. Any use in hair restoration is experimental and off-label.

Why Is Verteporfin Being Discussed for Hair Loss?

Interest in verteporfin for hair loss comes from research on wound healing and fibrosis. Fibrosis refers to the formation of scar tissue. In hair transplantation and scalp injury, scar formation can prevent new hair follicles from regenerating. Some researchers have proposed that if scarring can be reduced or altered, hair follicles might regenerate instead of forming fibrotic tissue.

The pivotal animal work was published in 2021 by Mascharak and colleagues in Science. Working in mouse full-thickness skin wounds, the team used single-cell transcriptomics and histology to map how wounds heal, and reported that blocking mechanical signalling through the YAP pathway with verteporfin shifted healing away from scarring and toward regeneration of skin structures, including hair follicles and glands. The authors concluded that preventing this fibroblast activation could promote regenerative rather than fibrotic healing (Mascharak et al., 2021).

That was an animal study, not a human hair loss trial. Mice have a greater capacity for skin regeneration than humans, and translating rodent results to people is complex. The work also concerned wound regeneration rather than androgenetic alopecia, which is the most common cause of hair loss and is driven primarily by sensitivity to dihydrotestosterone (DHT), a derivative of testosterone.

Human Evidence: Injection Alongside Dermal Wounding

The human material that circulates in hair loss discussions is not a clinical trial. It consists of two 2025 case reports in a low-tier dermatology journal that is not indexed in PubMed, so the reports could not be independently verified for this article. What follows describes what they are, not what they prove.

One report describes a single patient undergoing hair transplantation who received verteporfin injections at the surgical site on one side, with the untreated side used for comparison over roughly eight weeks. The other describes two men with androgenetic alopecia who received verteporfin injections into the scalp in combination with a wounding procedure, followed for several weeks, with hair density assessed by imaging. The authors reported density gains in previously hair-bearing and thinning areas and no regrowth in completely bald regions.

This article does not reproduce the doses, concentrations or injection protocols used in those reports. They come from unverified case reports of one and two patients, with no randomization, no blinding, no placebo control and no long-term follow-up; there is no established safe dose for injecting verteporfin into the scalp, and reproducing an experimental protocol outside medical supervision is dangerous.

What can be said about route of administration is narrow but clear: in the published human hair reports, verteporfin was injected at the site of surgical injury. It was not given orally, and it was not applied as a routine topical solution.

Laboratory Evidence: Effects on Hair Follicle Cells

A 2025 study in FASEB BioAdvances examined verteporfin in rat hair follicle neural crest stem cells under hypoxic (low oxygen) conditions. This was an in vitro laboratory study using rat-derived cells, not a clinical trial. The researchers treated cultured cells with verteporfin and measured proliferation and the expression of stemness markers. They reported that verteporfin reduced both proliferation and stem cell marker expression under hypoxic conditions.

That result cuts against the simple "verteporfin regenerates hair" reading: it suggests verteporfin can suppress certain stem cell activities in some contexts. The study did not evaluate hair regrowth in living humans, and laboratory conditions differ substantially from human scalp biology.

Is Verteporfin Used Topically or Orally for Hair Loss?

On the currently available published research, verteporfin is not used as an oral medication for hair loss. There are no published clinical trials of oral verteporfin for androgenetic alopecia, and the FDA-approved formulation is intravenous, for ophthalmic use.

There is also no approved topical verteporfin formulation for scalp application. Experimental discussions about topical or microneedling-assisted delivery exist in research and community forums, but the published human case reports to date used injection at a wound site.

So in research settings related to hair restoration, verteporfin has been given as an injection into the scalp, typically during or after procedures that create controlled injury. It is not used as a routine cream, foam, pill, or over-the-counter solution for pattern hair loss.

Safety: What Is Known and What Is Not

Verteporfin is a prescription photosensitizing drug developed for infusion under medical supervision. The Visudyne label warns that patients become temporarily photosensitive after a dose and must protect skin and eyes from bright light. Injecting it into the scalp is an unapproved route for an unapproved indication, and there is no published safety data for repeated scalp injection: no dosing standard, no long-term follow-up, and no monitoring protocol. Some community members discuss obtaining and self-administering it; this is unregulated, unsupervised and risky, and nothing in the published literature supports it.

Talk to a doctor or pharmacist before starting, stopping or combining verteporfin, and discuss any transplant surgeon's proposal to use it with a clinician who is not selling the procedure.

User Experiences From the Tressless Community

Within the Tressless community, verteporfin has generated significant discussion, particularly about its potential to reduce scarring after hair transplantation and possibly regenerate follicles in donor areas. Community posts from 2024 and 2025 reflect both excitement and skepticism.

Several threads discuss updates from surgeons experimenting with verteporfin during follicular unit transplantation (FUT) and follicular unit extraction (FUE). Users frequently mention its proposed mechanism of inhibiting YAP signalling, part of the Hippo pathway, which is involved in tissue growth and mechanical signalling. Some users speculate that combining verteporfin with microneedling may improve regenerative outcomes. Many commenters emphasize the lack of large, peer-reviewed randomized controlled trials.

Other community members point out that even if verteporfin improves donor-site healing, that does not mean it reverses advanced baldness such as Norwood stage 6 or 7. Several discussions note that completely bald areas in the published case reports did not show meaningful regrowth.

Overall, user sentiment in the community reads as cautious optimism alongside widespread acknowledgment that verteporfin remains experimental and is not a proven treatment for androgenetic alopecia.

Final Answer: How Is Verteporfin Used for Hair Loss?

Verteporfin is not approved as a topical or oral treatment for hair loss. In the limited human reports available, it has been injected into the scalp, usually in combination with dermal wounding during hair transplant procedures. Its current role in hair restoration is experimental and investigational.

Large, randomized, placebo-controlled clinical trials with long-term follow-up and standardized hair density measurement are still needed. Until such evidence exists and regulatory agencies evaluate it, verteporfin should not be considered an established treatment for hair loss.

References

Food and Drug Administration. (2000). Visudyne (verteporfin for injection) label, NDA 21-119. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21119lbl.pdf

Mascharak, S., desJardins-Park, H. E., Davitt, M. F., et al. (2021). Preventing Engrailed-1 activation in fibroblasts yields wound regeneration without scarring. Science, 372(6540), eaba2374. https://pubmed.ncbi.nlm.nih.gov/33888614/

Chan, W. M., Lai, T. Y. Y., Lai, R. Y. K., et al. (2008). Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: One-year results of a prospective study. Retina, 28(1), 85–93. https://pubmed.ncbi.nlm.nih.gov/18185143/

Inhibition of the Hippo pathway by verteporfin reduces the proliferation and stemness of rat hair follicle neural crest stem cells under hypoxia. (2025). FASEB BioAdvances. https://pubmed.ncbi.nlm.nih.gov/40060945/

Tressless Community. (2024–2025). Verteporfin discussions and clinical updates. https://community.tressless.com/t/verteporfin-phase-1-human-clinical-trial-in-the-works/1635

Tressless Reddit Community. (2024–2025). Verteporfin updates and transplant outcomes. https://reddit.com/r/tressless/comments/1dr9v9o/verteporfin_fut_9_month_update/